In the elderly, AML harbors high-risk mutations more frequently, such as DNMT3A, SRSF2, ASXL1, RUNX1 and TP53, confirming the role of genetics in explaining the poor outcomes in this age group [126,127,128]. This evidence concerns the gene DNMT3A and acute myeloid leukemia.